All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Epcoritamab plus pola-R-CHP as first-line treatment for patients with DLBCL: Results from the phase Ib/II EPCORE NHL-5 trial
|
The ongoing phase Ib/II EPCORE NHL-5 trial (NCT05283720) is evaluating the safety and efficacy of epcoritamab, a subcutaneous CD3 × CD20 bispecific antibody, in combination with antineoplastic agents in adult patients with NHL.1 The first results from Arm 3 of this trial, which included 37 adult patients with newly-diagnosed DLBCL treated with first-line epcoritamab plus pola-R-CHP, were presented at the SOHO 2024 Annual Meeting by Kerr.1 |
| Key learnings |
| Fixed-duration epcoritamab plus pola-R-CHP resulted in high response rates, with an ORR and CR rate of 100% and 88.6%, respectively. |
| Response rates were rapid, with a median time to response of 2.7 months; durable, with the median duration of CR not reached; and consistent across patient subgroups. |
| The safety profile was consistent with previous findings, with no DLTs, ICANS, CTLS, or Grade ≥3 CRS observed. Grade 1/2 CRS occurred in 49% of patients and all events were resolved. |
| The most common Grade ≥3 TEAE was neutropenia (65%); however, there were no resulting discontinuations. Rates of infection were low. |
| These results suggest that epcoritamab plus pola-R-CHP is well tolerated and effective as a first-line treatment for patients with DLBCL, with results comparing favorably to pola-R-CHP or R-CHOP alone. |
Abbreviations: CR, complete response; CRS, cytokine release syndrome; CTLS, clinical tumor lysis syndrome; DLBCL, diffuse large B-cell lymphoma; DLT, dose-limiting toxicity; ICANS, immune effector cell-associated neurotoxicity syndrome; NHL, non-Hodgkin lymphoma; ORR, objective response rate; pola-R-CHP, polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; SOHO, Society of Hematologic Oncology; TEAE, treatment-emergent adverse event.
- Kerr DA. First data from subcutaneous epcoritamab + polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-RCHP) for first-line diffuse large b-cell lymphoma (DLBCL): EPCORE NHL-5. Poster #ABCL-417. Presented at: Society of Hematologic Oncology 2024 Annual Meeting; Sep 4–7, 2024; Houston, US.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
16 votes - 19 days left ...
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox